SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27^th American Society of Gene & Cell Therapy Annual Meeting to be held in Baltimore, MD from May 7-11.

The following original research abstracts will be presented at the Poster Session:

• De-Risking Clinical Trials Leveraging MRI-Guided Intraparenchymal Delivery by Validating Commercially Available Infusion Pumps for Gene and Cell Therapy Infusions
  
• Intraparenchymal Infusions to Deep Brain Structures Using Low Field MRI (in collaboration with The Ohio State University Wexner Medical Center)

Additionally, the Company's technology will be featured in multiple partner posters and presentations. Conference attendees may visit the ClearPoint Neuro booth, #1033, to obtain a comprehensive list. Attendees may also pre-book meetings with our team directly here.

"The ASGCT Annual Meeting provides an extraordinary opportunity for us to connect with our existing partners, and attract potential new customers," stated Jeremy Stigall, Chief Business Officer at ClearPoint Neuro. "This year, in addition to the posters listed above, there are more than 10 partner-authored abstracts that are enabled by ClearPoint Neuro innovations."

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements within the context of the federal securities laws, which may include the Company's expectations for the future performance, market, and revenue of its products and services. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2024, which the Company intends to file with the Securities and Exchange Commission on or before May 15, 2024. The Company does not assume any obligation to update these forward-looking statements.

CONTACT: Contact:  Media Contact: Jacqueline Keller, Vice President of Marketing (888) 287-9109 ext. 4 info@clearpointneuro.com  Investor Relations: Danilo D'Alessandro, Chief Financial Officer (888) 287-9109 ext. 3 ir@clearpointneuro.com